Australia’s GBMA Working To Address Coronavirus Risks
Consumers Urged Not To ‘Panic Purchase’ And Stockpile Drugs
Australia’s GBMA off-patent industry association says its members are working to minimize the effects of coronavirus, amid reports of drug shortages and empty pharmacy shelves.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
As the Fight The Fakes Alliance holds its fifth annual “Fight The Fakes Week,” the IGBA has signed to become a new member of the association as it calls for fresh action to prevent falsified medicines from reaching patients.
Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.